A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

NCT04303741 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Camrelizumab
DRUG: Apatinib
DRUG: Eribulin

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University